PDF(Pubmed)
Abstract：
Acute respiratory distress syndrome (ARDS) is a deadly clinical presentation in sepsis, COVID, and other lung disorders where vascular fluid leakage is a severe problem. Recent findings by Shadab et al. in the JBC show that a well-known player in immune function, Syk, also regulates vascular leakage in response to sepsis. An existing FDA-approved inhibitor of Syk, fostamatinib, prevents the vascular leakage and improves survival in a mouse sepsis model, providing promise for ARDS treatment in the clinic.
摘要：
急性呼吸窘迫综合征（ARDS）是败血症的致命临床表现，COVID,和其他肺部疾病，其中血管液体渗漏是一个严重的问题。Shadab等人在JBC中的最新发现表明，在免疫功能方面，Syk,还调节血管渗漏以应对脓毒症。现有的FDA批准的Syk抑制剂，福司替尼,防止血管渗漏，提高小鼠败血症模型的存活率，为临床ARDS治疗提供了希望。
